title: [Hormonal therapy in breast cancer].
abstract: Hormonal therapy has been the first systemic treatment against breast cancer. Up to now Tamoxifen and ovarian supression/ablation were the best optionts we had to treat early breast cancer as advancer disease. The advent of aromatase inhibitors, new SERMS and antistrogen Fulvestrant have supoused a great advance in the treatment of this disease and at the same time have complicated the election of the optimal drug for each patient. This article tries to review the aviable treatment options insiting on its indications.
authors.affiliation: Area de tumores ginecológicos y de mama, Departamento de Oncología, Clínica Universitaria, Facultad de Medicina. Universidad de Navarra, Pamploma. jespinos@unav.es
authors.forename: J
authors.initials: J
authors.lastname: Espinós
authors.forename: C
authors.initials: C
authors.lastname: Reyna
authors.forename: S
authors.initials: S
authors.lastname: de la Cruz
authors.forename: C
authors.initials: C
authors.lastname: Oiler
authors.forename: A
authors.initials: A
authors.lastname: Hernández
authors.forename: O
authors.initials: O
authors.lastname: Fernández Hidalgo
authors.forename: M
authors.initials: M
authors.lastname: Santisteban
authors.forename: J
authors.initials: J
authors.lastname: García Foncillas
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen